Brain

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak

Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson’s Disease Data Readout Targeted for First Half of 2027

New BioSymetrics Inc. white paper and executed Master Collaboration Agreement establish an integrated roadmap spanning AI-driven patient stratification, human translational...

PharmaSmart Joins American Heart Association Innovators’ Network to Advance Evidence-Based Chronic Disease Screening and Community Health Technology & Innovation

American Heart Association consortium advances development of evidence-based health technology solutions ROCHESTER, NY / ACCESS Newswire / August 3, 2026...

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privosegtor in acute multiple sclerosis (MS) relapses,...

error: Content is protected !!